Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1958 1
1959 1
1968 1
1969 1
1971 1
1972 1
1974 11
1975 1
1976 1
1977 2
1979 3
1980 1
1981 1
1982 1
1988 1
1989 1
1994 1
1995 1
1996 3
1997 2
1998 1
1999 1
2000 2
2001 2
2004 1
2005 6
2006 3
2007 6
2008 3
2009 7
2010 7
2011 11
2012 9
2013 6
2014 4
2015 3
2016 8
2017 7
2018 5
2019 8
2020 6
2021 7
2022 9
2023 4
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

154 results

Results by year

Filters applied: . Clear all
Page 1
Metabolic Diversity in Human Non-Small Cell Lung Cancer Cells.
Chen PH, Cai L, Huffman K, Yang C, Kim J, Faubert B, Boroughs L, Ko B, Sudderth J, McMillan EA, Girard L, Chen D, Peyton M, Shields MD, Yao B, Shames DS, Kim HS, Timmons B, Sekine I, Britt R, Weber S, Byers LA, Heymach JV, Chen J, White MA, Minna JD, Xiao G, DeBerardinis RJ. Chen PH, et al. Among authors: peyton m. Mol Cell. 2019 Dec 5;76(5):838-851.e5. doi: 10.1016/j.molcel.2019.08.028. Epub 2019 Sep 26. Mol Cell. 2019. PMID: 31564558 Free PMC article.
AXL targeting restores PD-1 blockade sensitivity of STK11/LKB1 mutant NSCLC through expansion of TCF1+ CD8 T cells.
Li H, Liu Z, Liu L, Zhang H, Han C, Girard L, Park H, Zhang A, Dong C, Ye J, Rayford A, Peyton M, Li X, Avila K, Cao X, Hu S, Alam MM, Akbay EA, Solis LM, Behrens C, Hernandez-Ruiz S, Lu W, Wistuba I, Heymach JV, Chisamore M, Micklem D, Gabra H, Gausdal G, Lorens JB, Li B, Fu YX, Minna JD, Brekken RA. Li H, et al. Among authors: peyton m. Cell Rep Med. 2022 Mar 15;3(3):100554. doi: 10.1016/j.xcrm.2022.100554. eCollection 2022 Mar 15. Cell Rep Med. 2022. PMID: 35492873 Free PMC article.
Five-Year Outcomes after PCI or CABG for Left Main Coronary Disease.
Stone GW, Kappetein AP, Sabik JF, Pocock SJ, Morice MC, Puskas J, Kandzari DE, Karmpaliotis D, Brown WM 3rd, Lembo NJ, Banning A, Merkely B, Horkay F, Boonstra PW, van Boven AJ, Ungi I, Bogáts G, Mansour S, Noiseux N, Sabaté M, Pomar J, Hickey M, Gershlick A, Buszman PE, Bochenek A, Schampaert E, Pagé P, Modolo R, Gregson J, Simonton CA, Mehran R, Kosmidou I, Généreux P, Crowley A, Dressler O, Serruys PW; EXCEL Trial Investigators. Stone GW, et al. N Engl J Med. 2019 Nov 7;381(19):1820-1830. doi: 10.1056/NEJMoa1909406. Epub 2019 Sep 28. N Engl J Med. 2019. PMID: 31562798 Free article. Clinical Trial.
The Silent Mutation.
Peyton MA. Peyton MA. JAMA. 2021 May 4;325(17):1721-1722. doi: 10.1001/jama.2021.5484. JAMA. 2021. PMID: 33944872 No abstract available.
Co-occurring genomic alterations define major subsets of KRAS-mutant lung adenocarcinoma with distinct biology, immune profiles, and therapeutic vulnerabilities.
Skoulidis F, Byers LA, Diao L, Papadimitrakopoulou VA, Tong P, Izzo J, Behrens C, Kadara H, Parra ER, Canales JR, Zhang J, Giri U, Gudikote J, Cortez MA, Yang C, Fan Y, Peyton M, Girard L, Coombes KR, Toniatti C, Heffernan TP, Choi M, Frampton GM, Miller V, Weinstein JN, Herbst RS, Wong KK, Zhang J, Sharma P, Mills GB, Hong WK, Minna JD, Allison JP, Futreal A, Wang J, Wistuba II, Heymach JV. Skoulidis F, et al. Among authors: peyton m. Cancer Discov. 2015 Aug;5(8):860-77. doi: 10.1158/2159-8290.CD-14-1236. Epub 2015 Jun 11. Cancer Discov. 2015. PMID: 26069186 Free PMC article.
An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance.
Byers LA, Diao L, Wang J, Saintigny P, Girard L, Peyton M, Shen L, Fan Y, Giri U, Tumula PK, Nilsson MB, Gudikote J, Tran H, Cardnell RJ, Bearss DJ, Warner SL, Foulks JM, Kanner SB, Gandhi V, Krett N, Rosen ST, Kim ES, Herbst RS, Blumenschein GR, Lee JJ, Lippman SM, Ang KK, Mills GB, Hong WK, Weinstein JN, Wistuba II, Coombes KR, Minna JD, Heymach JV. Byers LA, et al. Among authors: peyton m. Clin Cancer Res. 2013 Jan 1;19(1):279-90. doi: 10.1158/1078-0432.CCR-12-1558. Epub 2012 Oct 22. Clin Cancer Res. 2013. PMID: 23091115 Free PMC article.
Efficacy and safety of a monthly buprenorphine depot injection for opioid use disorder: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
Haight BR, Learned SM, Laffont CM, Fudala PJ, Zhao Y, Garofalo AS, Greenwald MK, Nadipelli VR, Ling W, Heidbreder C; RB-US-13-0001 Study Investigators. Haight BR, et al. Lancet. 2019 Feb 23;393(10173):778-790. doi: 10.1016/S0140-6736(18)32259-1. Epub 2019 Feb 18. Lancet. 2019. PMID: 30792007 Clinical Trial.
Shift in the Night.
Peyton MA. Peyton MA. N Engl J Med. 2024 Mar 14;390(11):970-971. doi: 10.1056/NEJMp2311767. Epub 2024 Mar 9. N Engl J Med. 2024. PMID: 38466614 No abstract available.
Gefitinib versus cetuximab in lung cancer: round one.
Minna JD, Peyton MJ, Gazdar AF. Minna JD, et al. Among authors: peyton mj. J Natl Cancer Inst. 2005 Aug 17;97(16):1168-9. doi: 10.1093/jnci/dji247. J Natl Cancer Inst. 2005. PMID: 16106015 No abstract available.
Lentiviral-Driven Discovery of Cancer Drug Resistance Mutations.
Yenerall P, Kollipara RK, Avila K, Peyton M, Eide CA, Bottomly D, McWeeney SK, Liu Y, Westover KD, Druker BJ, Minna JD, Kittler R. Yenerall P, et al. Among authors: peyton m. Cancer Res. 2021 Sep 15;81(18):4685-4695. doi: 10.1158/0008-5472.CAN-21-1153. Epub 2021 Jul 23. Cancer Res. 2021. PMID: 34301758 Free PMC article.
154 results